

Yescarta® (axicabtagene ciloleucel) - New indication

- On March 5, 2021, <u>Kite, a Gilead Company, announced</u> the FDA approval of <u>Yescarta</u>
 (<u>axicabtagene ciloleucel</u>), for the treatment of adult patients with relapsed or refractory follicular
 lymphoma (FL) after two or more lines of systemic therapy.
 - This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- Yescarta is also approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from FL.
- The approval of Yescarta for the new indication was based on a single-arm, open-label study (ZUMA-5) that evaluated a single infusion of Yescarta in adult patients with relapsed or refractory FL after two of more lines of systemic therapy. Of 123 patients with FL who underwent leukapheresis, 120 received Yescarta. Of the 120 patients with FL infused with Yescarta, the 81 consecutive patients included in the primary efficacy analysis had at least 9 months of potential follow-up from date of first response. The primary endpoints were objective response rate (ORR) and duration of response (DOR).
 - In the primary efficacy population (n = 81), the ORR was 91% (95% CI: 83, 96). In all leukapheresed patients (n = 123), the ORR was 89% (95% CI: 83, 94).
 - The median DOR in the primary efficacy population was not estimable (95% CI: 20.8, not estimable).
- Yescarta carries boxed warnings for cytokine release syndrome and neurologic toxicities.
- Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy. Refer to the Yescarta drug label for dosing and administration recommendations.



optumrx.com

 $Optum Rx^{@}\ specializes\ in\ the\ delivery,\ clinical\ management\ and\ affordability\ of\ prescription\ medications\ and\ consumer\ health\ products.$ We are an $Optum^{@}\ company\ ---$ a leading provider of integrated health\ services. Learn more\ at\ optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.